LOTEPREDNOL ETABONATE AND TOBRAMYCIN

Post-LOE

loteprednol etabonate and tobramycin

Bausch + Lomb

ANDAOPHTHALMICSUSPENSION/DROPS

Approved

Dec 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

LOTEPREDNOL ETABONATE AND TOBRAMYCIN (loteprednol etabonate and tobramycin) by Bausch + Lomb is healing. Approved for inflammatory conditions of the palpebral, bulbar conjunctiva, cornea and 13 more indications. First approved in 2025.

Drug data last refreshed Yesterday

Mechanism of Action

healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular…

Pharmacologic Class:

Aminoglycoside Antibacterial

Indications (16)

Worked on LOTEPREDNOL ETABONATE AND TOBRAMYCIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.